NEWPORT BEACH,
Calif., June 20, 2024 /PRNewswire/ --
CureDuchenne, a global nonprofit committed to finding and
funding a cure for Duchenne muscular dystrophy, will host webinars
in English and Spanish for the Duchenne community after the U.S.
Food and Drug Administration (FDA) approved the expansion to
the label indication for ELEVIDYS (delandistrogene
moxeparvovec-rokl) from Sarepta Therapeutics to include individuals
with Duchenne muscular dystrophy (DMD) with a confirmed mutation in
the DMD gene who are at least 4 years of age.
The webinars will be moderated by Dr.
Michael Kelly, Chief Scientific
Officer at CureDuchenne with Dr. Diana
Castro, a board-certified neurologist and leading
neuromuscular physician, sharing the latest information and her
perspective as a physician treating patients with this gene
therapy. A representative from Sarepta Therapeutics will also join
by invitation as a guest for a Q&A session.
Register to attend:
- English Webinar: Tuesday, June 25,
2024 at 3:00pm PST
- Spanish Webinar: Tuesday, June 25,
2024 at 4:30pm PST
About CureDuchenne
Over twenty years ago, CureDuchenne was created with one goal: to
find and fund a cure for Duchenne muscular dystrophy, one of the
most common and severe forms of muscular dystrophy. Today,
CureDuchenne is recognized as a global leader in research,
patient care, and innovation for improving and extending the lives
of those with Duchenne. CureDuchenne's venture philanthropy
approach has advanced transformative treatments for Duchenne
muscular dystrophy, including 18 projects that advanced to human
clinical trials and multiple projects to overcome the limitations
of exon-skipping and gene therapy. In addition, CureDuchenne
contributed early funding to the first FDA-approved Duchenne drug,
pioneered the first and only Duchenne physical and occupational
therapist certification program and created an innovative
data-integrated biobank, accelerating research toward a cure. For
more information on how to help raise awareness and funds needed
for research, please visit cureduchenne.org, or follow us on
Facebook, Instagram, LinkedIn, and X.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/global-nonprofit-cureduchenne-to-host-informational-webinars-following-fda-label-expansion-of-sarepta-therapeutics-gene-therapy-elevidys-302178624.html
SOURCE CureDuchenne